Drugs / Add-back
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03070951 | May 2017 → Sep 2019 | uterine corpus leiomyoma | ObsEva SA | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Add-back | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03070951 ↗ |
| Route | Oral | “Add-back (E2 1 mg / NETA 0.5 mg) for oral administration once daily” NCT03070951 ↗ |